Tourmaline Bio, Inc.

TRML

US89157D1054

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
15.04 ^USD	+0.27%		+3.72%	-42.55%

05-16	Tourmaline Bio, Inc Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial	CI
05-13	Tourmaline Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Talaris Therapeutics, Inc. Announces the Resignation of Scott Requadt as Chief Executive Officer, Effective May 26, 2023

April 14, 2023 at 05:20 pm

Talaris Therapeutics, Inc. announced that Scott Requadt will be leaving as Chief Executive Officer, effective May 26, 2023.

Latest news about Tourmaline Bio, Inc.

Tourmaline Bio, Inc Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial	05-16	CI
Tourmaline Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Certain Restricted Stock Units of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	04-24	CI
Certain Options of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	04-24	CI
Certain Common Stock of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	04-24	CI
Wall Street Set to Open Higher After Fed Holds Interest Rates Steady; Initial Jobless Claims Lower Than Expected	03-21	MT
US Futures Trend Higher After Fed Decision to Hold Interest Rates Steady	03-21	MT
Top Premarket Decliners	03-21	MT
Tourmaline Reports Q4 Net Loss; Cash to Fund Operations Until 2027	03-19	MT
Tourmaline Bio, Inc. Plans to Commence a Phase 2 Trial Evaluating Quarterly Subcutaneous Dosing of TOUR006 in Patients with Elevated Cardiovascular Risk in the First Half of 2024	03-19	CI
Tourmaline Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Tourmaline Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-19	CI
Tourmaline Bio Insider Bought Shares Worth $3,250,000, According to a Recent SEC Filing	01-31	MT
Tourmaline Bio Prices $150 Million Common Stock Offering	01-25	MT
Tourmaline Bio, Inc.(NasdaqGS:TRML) added to NASDAQ Biotechnology Index	12-18	CI
Tourmaline Bio Joins Nasdaq Biotechnology Index	12-15	MT
Jefferies Starts Coverage on Tourmaline Bio with Buy Rating, $41 Price Target	12-15	MT
Tourmaline Bio, Inc. Appoints Clay Siegall to Serve as a Director	12-14	CI
Tourmaline Bio, Inc. Announces Resignation of Cariad Chester as Member of the Board of Directors	11-30	CI
Transcript : Tourmaline Bio, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 01:00 PM	11-29
Truist Starts Tourmaline Bio With Buy Rating, $43 Price Target	11-17	MT
North American Morning Briefing : Stock Futures -2-	11-16	DJ
Talaris Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Transcript : Tourmaline Bio, Inc. Presents at Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference, Nov-06-2023 03:50 PM	11-06
Tourmaline Bio Insider Bought Shares Worth $280,584, According to a Recent SEC Filing	23-10-27	MT

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Companyâs initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is also developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration. It is focused on two strategic paths for TOUR006, the first of which it refers to as FcRn+. Its second strategic path is cardiovascular inflammation.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.04 USD

Average target price

58.33 USD

Spread / Average Target

+287.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TOURMALINE BIO, INC.	-42.55%	386M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs

Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Biotechnology & Medical Research

Talaris Therapeutics, Inc. Announces the Resignation of Scott Requadt as Chief Executive Officer, Effective May 26, 2023

Latest news about Tourmaline Bio, Inc.

Chart Tourmaline Bio, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs